$200M usually isn't enough for even one drug - $500M is on the low end, and not all drug development works out. So it's plausible that the money is better allocated here than in treatments.

But also, from the article: "Based on some of 23andMe’s newer hires, we wouldn’t be shocked to see the company dive into drug development, either."